gnc glp 1 products Supergut Unflavored GLP-1 Booster 15 Gut Level GLP GNC Debuts New Section Dedicated

Current evidence from regulatory bodies, including the MHRA and EMA, provides reassurance regarding the safety profile of GLP-1 therapies

Cardiovascular outcome trials (CVOTs) typically assess the risk of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke, collectively known as three-point major adverse cardiovascular events (MACE)

Obesity Medicine

Sun Protection Protocol for Wegovy and GLP-1 Patients Given the increased UV vulnerability and potential for photosensitizing co-medications, a robust and layered sun protection strategy is paramount for Wegovy and other GLP-1 patients

Gabriel Chiu, D.O